WuXi PharmaTech Inc., the Shanghai-based CRO, announced its Q2 financial results, showing that the company increased its revenues 134% to $70.8 million and enjoyed an 81% rise in non-GAAP net income, which came in at $15.5 million or 21 cents per ADS. The results were higher than analysts’ estimates. In the conference call, WuXi dodged questions about the performance of its AppTec acquisition and dangled the prospect of a big contract in the future. More details...

Stock Symbol: (NYSE: WX)